OC-001 is an experimental immunotherapy drug that works by targeting a molecule called TNF. This type of treatment works by preventing inflammation in the body and enhancing the anti-cancer effect of certain other treatments.
Since this drug is still in the clinical trial phase, it has the placeholder name OC-001 rather than a commercial trade name.
In this trial, OC-001 may be combined with a drug from a class of immunotherapies called PD-L1 Inhibitors. These are widely used in the treatment of Kidney Cancer (i.e. Nivolumab) and enable the immune system to better recognize and destroy cancer cells.
This study will have two treatment groups that will be assigned by the physician handling your care:
Group 1: OC-001 alone
Group 2: OC-001 with a PD-L1 Inhibitor
In order to maximize effectiveness and minimize side effects, different doses of each drug will be used to determine the optimal dosage of these medications.
There is no control group in the study, so there will be no “placebo”, and all patients will receive treatment.
- Any subtype of kidney cancer
- Advanced kidney cancer that cannot be removed by surgery
- Must have received at least one previous immunotherapy treatment
- Must not have received more than 4 different drug treatments
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentreCross Cancer Institute||Principal InvestigatorQuincy Chu||LocationEdmonton, AB||Trial StatusRecruiting|
|Hospital / Cancer CentrePrincess Margaret Hospital||Principal InvestigatorAmit Oza||LocationToronto, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreOttawa Hospital Cancer Centre (OHRI)||Principal InvestigatorDerek Jonker||LocationOttawa, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreJewish General Hospital||Principal InvestigatorWilson Miller||LocationMontreal, QC||Trial StatusRecruiting|
|Hospital / Cancer CentreCentre hospitalier de l'Université de Montréal (CHUM)||Principal InvestigatorDiane Provencher||LocationMontreal, QC||Trial StatusRecruiting|